Antibiotic :: New drug application submitted for investigational antibiotic Doripenem

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia, a pneumonia that is acquired in a hospital or other healthcare setting.

Immunity :: Newly found sensing system enables certain bacteria to resist human immune defenses

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, have discovered a survival mechanism in a common type of bacteria that can cause illness. The mechanism lets the bacteria protect itself by warding off attacks from antimicrobial peptides (AMPs), which are defense molecules sent by the body to kill bacteria.

Allergy :: House dust may protect against allergic disease early in life

Endotoxin, a toxic substance made by certain types of bacteria, may reduce the risk of developing the allergic skin condition eczema or wheezing in children if they are exposed to it up to age 3, suggests a study presented at the American Thoracic Society 2007 International Conference, on Sunday, May 20.

Atrial Fibrillation :: Ottawa aggressive protocol for acute atrial fibrillation is successful

There is no consensus on Emergency Department management of acute atrial fibrillation (AAF) or atrial flutter (AAFL). The Ottawa Aggressive Protocol, consisting of an IV procainamide infusion of 1 gram over 1 hour, electrical cardioversion, if necessary, by ED staff and discharge from the ED with outpatient cardiology follow-up, may be a safe and effective treatment for AAF and AAFL.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack